0
December 1991, Vol 151, No. 12 >
ARTICLE | December 1991

Octreotide Is Cost-effective Therapy in Diabetic Diarrhea

Paul E. Michaels, PharmD; Robert B. Cameron, MD
Arch Intern Med. 1991;151(12):2469. doi:10.1001/archinte.1991.00400120103019.
Text Size: A A A
Published online
Article
References
Comments

To the Editor. —  We wish to commend Ogbonnaya and Arem1 for their review on the pathophysiology, diagnosis, and management of diabetic diarrhea that appeared in the February 1990 issue of the ARCHIVES. Some clarifications, however, need to be made regarding the authors' discussion on the role of somatostatin and somatostatin analogues in the management of diabetic diarrhea. Referring to a letter published by Tsai et al,2 Ogbonnaya and Arem cite these authors as administering somatostatin in doses of 50 to 75 mg twice a day, while Tsai et al report administering octreotide (not somatostatin) by subcutaneous injection in doses of 50 to 75 μg (ie, micrograms [mcg vs μg], not milligrams) twice a day. A point to be made is that somatostatin and octreotide are separate compounds.3 Somatostatin has been identified as being both a 14- and 28-amino acid peptide (as well as other prosomatostatins) with

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Correspondence

Submit a Letter
CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Clear Answers | Save For Later
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs

More Listings at
JAMACareerCenter.com >

© 2013 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems